Thermo Fisher Scientific has finalized the acquisition of Olink Holding AB, an operation designed to fundamentally strengthen the group's capabilities in the high-growth proteomics market. The strategic rationale for this transaction centers on a "platform-complementarity" play, merging the target's industry-leading protein analysis technology with the group’s established leadership in mass spectrometry and life sciences instrumentation. This fusion effectively creates a specialized powerhouse in the protein biomarker discovery arena, providing the organization with the necessary technical operational depth to address the increasing demand for precision medicine solutions. This operation allows the group to execute a definitive structural expansion into the high-throughput proteomics sector, specifically targeting the installed base of sequencing systems. By incorporating the target's proprietary PEA technology, the organization can now provide a more robust and integrated solution set for researchers looking to accelerate scientific breakthroughs. The maneuver optimizes the group's financial profile through the realization of significant revenue and cost synergies while leveraging its global commercial machine to drive international market penetration. Ultimately, the partnership solidifies the group’s standing as a primary enabler of proteomic innovation, bridging the gap between sophisticated laboratory-scale diagnostics and industrialized pharmaceutical research standards.

The transaction values OLINK at an EV/Revenue multiple of LOGIN.

This transaction is part of the Industry & Manufacturing industry, which currently tracks an average EBITDA multiple of 10.5x since the beginning of 2026, 3.1% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.